drugset / Trial / NCT05721443
Cetuximab Plus Dalpicilib in Patients With HPV Negative, PD-1 Resistant R/M HNSCC
Phase 2
Completed
28 enrolled
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
NaSingle-groupOpen-labelTreatment
Summary
This study is the first clinical study in PD-1 resistant patients with head and neck squamous cell carcinoma with drugs targeting EGFR signaling pathway combined with CDK4/6 inhibitors, which explores the new combination therapies urgently needed in clinical practice and lays a foundation for subsequent studies, with important scientific research significance and clinical value.
Timeline
- Start
- 2022-12-01
- Primary completion
- 2024-11-01
- Completion
- 2025-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 250 mg/m2 | Intravenous |
| Subject | Dalpiciclib | Small molecule | 150 mg | — |